drugset / Trial / NCT00924586

Study of ONO-1101 in Patients Scheduled for Multi-Slice Computed Tomography (CT)

NCT00924586

Phase 3 Completed 258 enrolled Ono Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindDiagnostic

Summary

The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in patients scheduled for multi-slice CT, in a double-blind, randomized, placebo-controlled, parallel group, multi-center study.

Timeline

Start
2009-06
Primary completion
2010-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Landiolol Small molecule 0.125 mg/kg Intravenous